Eli Lilly’s weight-loss drug cut the risk of developing type 2 diabetes by 94% in prediabetic adults who were overweight or obese after three years of weekly injections, the company disclosed in a statement on Tuesday. The Indianapolis, Indiana-based company said the data comes from the longest completed trial of the drug, adding that it reinforces the long-term benefits of tirzepatide — the chemical name of its Zepbound and Mounjaro treatments. Shares of the company rose 1.6% to $936.
In the trial involving 1,032 adults, patients who received weekly injections of the Lilly drug showed a 94% reduction in the risk of progression to type 2 diabetes compared to placebo up to week 176. The data comes amid concerns that patients reduce the use of weight-loss drugs over time. Reuters reported in July that only one in four U.S. patients prescribed Novo Nordisk’s Wegovy or Ozempic for weight loss were still taking the popular medications two years later.
Canada Canada Latest News, Canada Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Forbes - 🏆 394. / 53 Read more »